Biogen Inc. (ETR:IDP)
Germany
· Delayed Price · Currency is EUR | Market Cap | 15.91B |
| Revenue (ttm) | 9.08B |
| Net Income (ttm) | 1.37B |
| Shares Out | n/a |
| EPS (ttm) | 9.36 |
| PE Ratio | 11.63 |
| Forward PE | 8.10 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 37 |
| Average Volume | 299 |
| Open | 110.05 |
| Previous Close | 108.75 |
| Day's Range | 108.05 - 110.10 |
| 52-Week Range | 99.00 - 220.00 |
| Beta | 0.15 |
| RSI | 39.12 |
| Earnings Date | Jul 31, 2025 |
About Biogen
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar r... [Read more]
Financial Performance
In 2024, Biogen's revenue was $9.68 billion, a decrease of -1.62% compared to the previous year's $9.84 billion. Earnings were $1.63 billion, an increase of 40.57%.
Financial numbers in USD Financial StatementsNews
Biogen: Investors Are Missing The Bigger Picture
21GRAMS Wins Its First Gold Lion for Branded Pharma Campaign at Cannes Lions International Festival of Creativity
Biogen’s “Friedreich’s Back” Takes Top Honors in Pharma; 21GRAMS Named No. 2 Healthcare Agency and Real Chemistry Ranked No. 2 Healthcare Network Globally on Creative Community’s Biggest Stage CANNES,...
20 companies in the S&P 500 whose investors have gained the greatest rewards from stock buybacks
These companies have reduced their share counts the most over the past 10 years
Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to
What Does the Market Think About Biogen?
Biogen's (NYSE: BIIB) short percent of float has risen 13.95% since its last report. The company recently reported that it has 3.80 million shares sold short , which is 3.35% of all regular shares th...
Biogen, UCB Take A Leap In Lupus With Promising Phase 3 Results
UCB SA (OTC: UCBJY) (OTC: UCBJF) (Euronext Brussels: UCB) and Biogen Inc . (NASDAQ: BIIB) on Thursday presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizum...
Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity
BRUSSELS and CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today presented additional detailed results from the Phase 3 PHOENYCS GO st...
Biogen Inc. (BIIB) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors.
Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI
Michael Yee, Jefferies senior biotech analyst, joins CNBC's 'Squawk on the Street' to discuss how AI could fuel drug discovery and development, the timeline for when pharmaceutical companies could see...
Biogen and City Therapeutics partner to develop RNAi therapies
Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies
Collaboration leverages City Therapeutics' next-generation RNAi engineering technologies and Biogen's extensive drug development expertise Collaboration leverages City Therapeutics' next-generation RN...
Eli Lilly’s Alzheimer’s drug cleared in Australia despite setback for Biogen
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up t...
Jeito Capital Strengthens Leadership for Next Chapter of Growth: Mehdi Ainouche Promoted to Partner, Julien Elric to Senior Principal
Paris, May 12 , 2025 - Jeito Capital (“Jeito”), a global leading independent Private Equity fund dedicated to biopharma, is pleased to announce the promotion of Mehdi Ainouche to Partner and Julien E...
Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) on Thursday reported a first-quarter 2025 adjusted EPS loss of 1 cent, beating the consensus loss of $(1.03) . The company reported quarterly sales of $594....
Biogen Beats Q1 Earnings Expectations As Two Newcomer Drug Sales Spike, Avoids Tariff Impact
Biogen Inc. (NASDAQ: BIIB) reported on Thursday that the first quarter of 2025 adjusted earnings per share was $3.02. That’s down from $3.67 a year ago, beating the analyst consensus of $2.52 . The c...
Biogen outlines growth strategy with LEQEMBI and SKYCLARYS advancements for 2025
Biogen Inc. (BIIB) Q1 2025 Earnings Call Transcript
BIIB Earnings: Biogen Q1 2025 adj. profit drops despite higher revenues
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) Thursday reported a year-over-year decrease in adjusted profit for the first quarter of 2025, despite an increase in revenues. Total revenue rose 6% year-...
Biogen Inc. 2025 Q1 - Results - Earnings Call Presentation
Earnings Snapshot: Biogen FY profit outlook misses estimates even as Q1 beats
Biogen Non-GAAP EPS of $3.02, revenue of $2.43B
Biogen beats quarterly profit estimates on strong demand for rare disease drugs
Biogen beat first-quarter profit and revenue expectations on Thursday, as strong demand for its rare disease drugs helped offset declining sales of its multiple sclerosis drugs.
Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar
Biogen stock could pop Thursday after the biotech company beat first-quarter expectations, including strong sales for two newcomer drugs.